Free Trial
NASDAQ:CMRX

Chimerix Q4 2024 Earnings Report

Chimerix logo
$8.54 0.00 (0.00%)
As of 04/21/2025

Chimerix EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Chimerix Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.31 million
Beat/Miss
Missed by -$254.00 thousand
YoY Revenue Growth
N/A

Chimerix Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 21, 2025
Conference Call Time
6:00AM ET

Upcoming Earnings

Chimerix's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Chimerix Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Chimerix reports Q4 EPS (25c), consensus (28c)
See More Chimerix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chimerix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chimerix and other key companies, straight to your email.

About Chimerix

Chimerix (NASDAQ:CMRX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel antiviral therapeutics and immune-modulating agents. The company leverages its proprietary lipid conjugate platform to enhance the delivery and potency of small-molecule drugs, with a primary focus on serious viral pathogens and inflammatory conditions. Through this technology, Chimerix aims to address unmet medical needs by improving safety profiles and reducing dosing frequency compared to conventional treatments.

Chimerix’s lead product, Tembexa (brincidofovir), received regulatory approval for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Rule, marking a significant milestone as a medical countermeasure for potential biothreats. The company’s pipeline also includes CMX521, an oral antiviral candidate targeting norovirus, and additional preclinical programs designed to combat respiratory viruses and emerging infectious diseases. In parallel, Chimerix is advancing DSTAT, an immunomodulatory agent being explored for its potential to reduce inflammation and improve outcomes in severe viral infections.

In pursuing global health solutions, Chimerix collaborates with government agencies, research institutions and biopharmaceutical partners across North America, Europe and Asia. These partnerships support clinical development, regulatory strategy and manufacturing scale-up, ensuring broad access to critical therapies. The company’s supply of Tembexa is incorporated into national strategic stockpiles, reflecting its role in public health preparedness and biodefense initiatives.

Founded in 2000 and headquartered in Durham, North Carolina, Chimerix has built a multidisciplinary team of virologists, chemists and clinical development experts. Dean Y. Li, M.D., serves as President and Chief Executive Officer, guiding the company’s scientific vision and growth strategy. Under his leadership, Chimerix continues to explore innovative drug delivery approaches and expand its pipeline to deliver safe and effective treatments to patients confronting life-threatening viral diseases and inflammatory conditions.

View Chimerix Profile

More Earnings Resources from MarketBeat